Geron Corp (GERN)
NASDAQ:GERN
GERN Stock Chart & Stats
$1.54
<$0.01(0.15%)
At close: 4:00 PM EST
$1.54
<$0.01(0.15%)
Day’s Range― - ―
52-Week Range$1.04 - $2.01
Previous CloseN/A
Volume1.63M
Average Volume (3M)18.90M
Market Cap
$986.44M
Enterprise Value$1.16B
Total Cash (Recent Filing)$359.80M
Total Debt (Recent Filing)$251.57M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
May 11, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding640,544,700
10 Day Avg. Volume19,669,984
30 Day Avg. Volume18,902,183
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue6.30
Enterprise Value/Gross Profit7.33
Enterprise Value/Ebitda-22.24
Forecast
1Y Price Target
$3.25Price Target Upside111.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$229.32M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And LiquiditySubstantial cash reserves, access to additional debt capacity, and disciplined cost reductions provide financial flexibility to support commercialization while strategic options are evaluated.
Clinical Progress And Launch MomentumInterim clinical results remain on track and the commercial launch shows rising demand with a growing share of earlier‑line patients, indicating potential for accelerating uptake toward a larger peak opportunity.
Commercial ExecutionExpanded sales force and new commercial leadership are strengthening promotional efforts and increasing ordering accounts in high‑volume community centers, supporting broader adoption of the therapy.
Bears Say
Patient Population UncertaintyUncertainty about the mix of treated patient populations and typical therapy duration creates doubt around the drug's achievable peak sales and long‑term revenue potential.
Pricing And Net‑revenue PressureRising gross‑to‑net adjustments and contracting with group purchasing organizations are reducing net revenue per unit and could weaken margins and reinvestment capacity.
Revenue ShortfallReported revenue and unit sales missed analyst expectations and company sales guidance, which undermines near‑term top‑line growth visibility.
Geron News
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.04 and its highest was $2.01 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $986.44M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is May 11, 2026 which is in 45 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Feb 25, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.03 by -$0.02.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp does not currently pay dividends.
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -0.02.
How many shares outstanding does Geron Corp have?
Geron Corp has 640,544,700 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.03. Following the earnings report the stock price went down -11.795%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GERN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.25 (111.04% Upside)
$3.25 (111.04% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 5.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.41%
12-Months-Change
Fundamentals
Return on Equity
-34.23%
Trailing 12-Months
Asset Growth
-3.93%
Trailing 12-Months
Company Description
Geron Corp
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
GERN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and clinical story: substantial year-over-year revenue growth as Rytelo completed its first full commercial year, meaningful Q4 demand and prescriber gains, clear 2026 revenue guidance and a focused second-line strategy targeting ~8,000 U.S. patients. Clinical progress (fully enrolled IMPACT MF trial, multiple ISTs and upcoming real-world data) and a streamlined cost structure that targets lower operating expenses in 2026 are further positives. Offsetting risks include an operating loss in 2025 (expenses exceed revenue), a ~20% decline in cash year-over-year and higher gross-to-net deductions (expected to remain in the high teens to low 20s), plus European reimbursement and pricing uncertainty. On balance, the company appears positioned for growth with manageable near-term financial and access risks.View all GERN earnings summariesGERN Stock 12 Month Forecast
Average Price Target
$3.25
▲(111.04% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
11.09% Mutual Funds
37.85% Other Institutional Investors
36.10% Public Companies and
Individual Investors